Table II. PCNSL survival analysis based on expression of HGAL, LMO2 and BCL6 proteins.
Variable | PFS | PFS | OS | OS |
---|---|---|---|---|
Hazard ratio (95% CI) | p-value | Hazard ratio (95% CI) | p-value | |
HGAL | ||||
Negative (reference) | 1.0 | 0.99 | 1.0 | 0.76 |
Positive | 1.0 (0.45 – 2.22) | 0.89 (0.42 – 1.88) | ||
LMO2 | ||||
Negative (reference) | 1.0 | 0.071 | 1.0 | 0.027 |
Positive | 0.50 (0.23 – 1.06) | 0.44 (0.21 – 0.91 | ||
BCL6 | ||||
Negative (reference) | 1.0 | 0.006 | 1.0 | 0.055 |
Positive | 0.35 (0.16 – 0.74) | 0.49 (0.24 – 1.02) | ||
LMO2/BCL6 combined | ||||
Double negative (reference) | 1.0 | 0.004 | 1.0 | 0.006 |
One marker positive | 0.37 (0.15 – 0.90) | 0.31 (0.12 – 0.77) | ||
Double positive | 0.24 (0.10 – 0.61) | 0.32 (0.13 – 0.75) |
PFS, progression-free survival; OS, overall survival